RANDOMIZED STUDY OF VAC VS VAC ALTERNATING WITH VTC IN INTERMEDIATE RISK RMS

中等风险 RMS 中 VAC 与 VAC 与 VTC 交替的随机研究

• 批准号: 7375483
• 负责人: YOUSIF H MATLOUB
• 金额: $ 5.05万
• 依托单位: UNIVERSITY OF WISCONSIN-MADISON
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-12-01 至 2006-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7375483
• 关键词: RANDOMIZED; STUDY; VAC; VS; ALTERNATING

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This study is closed to further accrual. (Clinical trial summary from the National Cancer Institute's PDQ database) Drugs used in chemotherapy, such as dactinomycin, cyclophosphamide, vincristine, and topotecan, use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which combination chemotherapy regimen is more effective in treating rhabdomyosarcoma. This randomized phase III trial is comparing two different combination chemotherapy regimens to see how well each works in treating patients with previously untreated rhabdomyosarcoma or sarcoma.

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子弹和调查员（PI）可能已经从其他NIH来源获得了主要资金，因此可以在其他清晰的条目中代表。列出的机构适用于该中心，这不一定是调查员的机构。这项研究已关闭以进一步应计。 （来自国家癌症研究所的PDQ数据库的临床试验摘要）用于化学疗法中的药物，例如Dactinymycin，环磷酰胺，长春新碱和拓扑甘油，使用不同的方法来阻止肿瘤细胞分裂，从而停止生长或死亡。尚不清楚哪种组合化疗方案在治疗横纹肌肉瘤方面更有效。 这项随机III期试验正在比较两种不同的组合化疗方案，以了解每个人在治疗先前未经治疗的横纹肌肉瘤或肉瘤的患者方面的效果。